Deal economics for Orbis include >$1.4B upfront and milestones, tiered royalties, and a strategic Novo equity investment, ...
The first phase of the GLP-1 revolution was a race to develop better drugs but the next may be a race to control what happens ...
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon ...
Regulatory action establishes finerenone as the only non-steroidal MRA indicated for CKD with either type 1 or type 2 diabetes. Fine-One randomized adults with T1D-CKD to finerenone 10/20 mg daily vs ...
Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, ...
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership ...
Novo Nordisk and Anthropic will co-develop AI solutions for defined discovery bottlenecks, focusing on biological reasoning, scientific workflows, and accelerating progression from research insights ...
Sling Therapeutics closes a $123 million Series C to advance linsitinib, while Circle Pharma raises an oversubscribed $92.5 ...
The biopharmaceutical industry is undergoing a profound transformation, driven by the emergence of agentic artificial intelligence (AI). Unlike traditional AI models that require continuous human ...
CGT commercial trajectories are set years before approval — and every development decision is an access decision.
Three years ago, when Pharmaceutical Executive last profiled Wendy Short Bartie, she was newly installed as senior vice ...
Novartis investors are placing increased pressure on Novartis’ dealmaking strategy after facing setbacks to drugs acquired ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results